AGENUS INC Proceeds from (Repayments of) Debt
AGENUS INC (AGEN) reported Proceeds from (Repayments of) Debt of -$1.11 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfDebt · last filed 2015-08-03
- AGENUS INC proceeds from (repayments of) debt for the quarter ending 2015-06-30 was -$277.78K.
- AGENUS INC proceeds from (repayments of) debt for the quarter ending 2015-03-31 was -$833.33K.
- AGENUS INC proceeds from (repayments of) debt for the quarter ending 2014-09-30 was -$833.33K.
- AGENUS INC proceeds from (repayments of) debt for the quarter ending 2014-06-30 was -$833.33K.
| Period end | Proceeds from (Repayments of) Debt 3 month | Proceeds from (Repayments of) Debt 6 month | Proceeds from (Repayments of) Debt 9 month |
|---|---|---|---|
| 2015-06-30 | -$277.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-03 | -$1.11M 10-Q · filed 2015-08-03 | |
| 2015-03-31 | -$833.33K 10-Q · filed 2015-05-01 | ||
| 2014-09-30 | -$833.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$1.67M derived: sum of 2 quarters · filed 2015-08-03 | -$2.50M 10-Q · filed 2014-10-31 |
| 2014-06-30 | -$833.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-03 | -$1.67M 10-Q · filed 2015-08-03 | |
| 2014-03-31 | -$833.33K 10-Q · filed 2015-05-01 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$10.00M 10-Q · filed 2014-10-31 | |
| 2013-06-30 | -$10.00M 10-Q · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |